NOMAD Power Solutions, Inc.(NMAD)

Biotechnology · Boca Raton, FL

$4.30+0.29 (+7.10%)

Delayed quote: Oct 6, 2026, 2:22 PM EDT

PS Ratio: N/A

Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/S ratio is N/A as of 2026-10-06T18:27:42.909Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:27:42.909Z.

Quote observation: 2026-10-06T18:22:56.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 53,147,506
TTM revenue · period ending 2026-06-30: 0

FMP input reference: f372f39edc86e990c580289f142e0fc1828f45467bffd466be8591b91f734aee

P/E Ratio|Gross Margin|Revenue Growth|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

NMAD PS Ratio Metrics

PS RATIO

N/A

NMAD Competitors' PS Ratio

NMAD

NOMAD Power Solutions, Inc.

Current

Market Cap

$53.15M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BTMD

biote Corp.

vs NMAD

Market Cap

$51.83M

PS Ratio

0.28

TTM Avg

0.38

3Y Avg

0.71

5Y Avg

0.59

DWTX

Dogwood Therapeutics, Inc.

vs NMAD

Market Cap

$52.46M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

EXOZ

eXoZymes, Inc.

vs NMAD

Market Cap

$51.42M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RANI

Rani Therapeutics Holdings, Inc.

vs NMAD

Market Cap

$53.50M

PS Ratio

10.97

TTM Avg

47.77

3Y Avg

38.29

5Y Avg

68.25

ALDX

Aldeyra The

vs NMAD

Market Cap

$52.73M

PS Ratio

N/A

TTM Avg

4.74

3Y Avg

4.40

5Y Avg

4.40

TENX

Tenax Therapeutics, Inc.

vs NMAD

Market Cap

$51.19M

PS Ratio

N/A

TTM Avg

1214.61

3Y Avg

1444.04

5Y Avg

930.10

IMA

ImageneBio Inc

vs NMAD

Market Cap

$53.24M

PS Ratio

N/A

TTM Avg

51.20

3Y Avg

31.27

5Y Avg

27.74

ELOX

Eloxx Pharmaceuticals, Inc.

vs NMAD

Market Cap

$50.86M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CLNN

Clene Inc.

vs NMAD

Market Cap

$50.83M

PS Ratio

258.04

TTM Avg

342.08

3Y Avg

169.55

5Y Avg

218.69

NAME	MARKET CAP	PS RATIO	TTM	3Y	5Y
NOMAD Power Solutions, Inc. (NMAD)	$53.15M	N/A	N/A	N/A	N/A
biote Corp. (BTMD)vs ›	$51.83M	0.28	0.38	0.71	0.59
Dogwood Therapeutics, Inc. (DWTX)vs ›	$52.46M	N/A	N/A	N/A	N/A
eXoZymes, Inc. (EXOZ)vs ›	$51.42M	N/A	N/A	N/A	N/A
Rani Therapeutics Holdings, Inc. (RANI)vs ›	$53.50M	10.97	47.77	38.29	68.25
Aldeyra The (ALDX)vs ›	$52.73M	N/A	4.74	4.40	4.40
Tenax Therapeutics, Inc. (TENX)vs ›	$51.19M	N/A	1214.61	1444.04	930.10
ImageneBio Inc (IMA)vs ›	$53.24M	N/A	51.20	31.27	27.74
Eloxx Pharmaceuticals, Inc. (ELOX)vs ›	$50.86M	N/A	N/A	N/A	N/A
Clene Inc. (CLNN)vs ›	$50.83M	258.04	342.08	169.55	218.69

How this was calculated

Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.

Revenue calculation and filing references
Fiscal period	Revenue	Source
Q3 FY2025Period ended 2025-09-30	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-09-30
Q4 FY2025Period ended 2025-12-31	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-31
Q1 FY2026Period ended 2026-03-31	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31
Q2 FY2026Period ended 2026-06-30	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-30
TTM revenue	$0

The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.

These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.

Sales Valuation

P/S Ratio

N/A

Market Cap / Trailing Twelve-Month Revenue

PS Ratio Formula & Definition

PS Ratio = Market Cap / Revenue (TTM)

The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

PS Ratio: N/A

NMAD PS Ratio Metrics

NMAD Competitors' PS Ratio

Sales Valuation

PS Ratio Formula & Definition

Related Metrics